Fibrocell Science Inc (NASDAQ:FCSC), A reduction of 845,388 shares or 24.4% was observed in the short interest of Fibrocell Science Inc The interest on June 15,2016 came in at 2,622,567 shares and as per the average daily trading of 422,574 shares, the days to cover are 6. The reduced interest is 9.6% of the floated shares. The data of May 31,2016 put the interest at 3,467,955 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Fibrocell Science Inc (NASDAQ:FCSC): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.95 and $0.91 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.06. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.03, notching a gain of 5.89% for the day. The total traded volume was 2,555,596 . The stock had closed at $0.97 on the previous day.
The company shares have dropped -79.40% from its 1 Year high price. On Aug 5, 2015, the shares registered one year high at $7.60 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $1.73 and the 200 Day Moving Average price is recorded at $2.70.
Stocks of Fibrocell Science Inc (NASDAQ:FCSC) rallied by 1.98% during the past week but lost 51.64% on a 4-week basis. The company has outperformed the S&P 500 by 3.67% in the past week but underperformed the index by 50.18% in the last 4 weeks.
Fibrocell Science, Inc. (Fibrocell) is an autologous cell therapy company focused on developing treatments for rare and serious skin and connective tissue diseases. The Companys lead orphan gene therapy program is in late-stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). In addition to its gene therapy program, the Company is pursuing the medical application of azficel-T for vocal cord scarring using its autologous fibroblast technology. The Company is also in pre-clinical development for its second gene therapy program for linear scleroderma. The Companys collaboration with Intrexon Corporation, a synthetic biology company, includes using genetically modifying autologous fibroblast cells to express collagen VII that is missing or inactive from patients with RDEB.